Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Adjusted Net Income Guidance," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

REVENUES:

Sales $485,042 $435,194 $918,939 $859,073

Other reve
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a ... , is teaming up with the Heartland Blood ... in its annual blood drive. The drive takes place ... Chevrolet location from 8 a.m. - 2 p.m. ... Bill Jacobs Auto annual blood drive is an ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... company developing antibody-drug conjugates for cancer, today announced the ... Board of Directors. Dr Reynolds has over 20 years, ... as Chief Medical Officer at Seattle Genetics. ... time for Oxford BioTherapeutics, as the company completes its ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two ... education have continued their sponsorship of an annual ... to stimulate interest in, and access to, innovative ... problems experienced by engineers. , TEAMS: Tests ... a program administered by the Technology Student Association ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... the treatment of tinnitus. Patients listen to sound ... and over a period of weeks to months, their ... Sound Therapy in two forms: Notched Music and Notched ... release of a new form of Tailor-Made Notched Sound ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... and Case Volumes Increase 53% and 52% Respectively ... ... Clarient, Inc.,(Nasdaq: CLRT ), a premier technology and services resource ... fourth quarter and year ended December 31, 2007.,Revenue from continuing operations ...
... -- Conference Call on Monday, March 31, ... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... months and twelve months ended December 31,2007., Highlights ... million, up 118% year-over-year -- Record full year ...
... Eisai Co.,Ltd. and its U.S. subsidiary Eisai ... District Court for the District of New,Jersey has ... motion for a,preliminary injunction in its patent infringement ... (collectively,"Teva"), concerning Aricept(R) (generic name: donepezil hydrochloride,tablets)., ...
Cached Biology Technology:Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 2Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 4Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 5Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 6Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 7Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 8Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 9Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 2Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 3Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 4Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 5Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 6Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 7Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 8Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals 3
(Date:4/15/2014)... (April 15, 2014) The American Association of ... winners. All awards will be presented during the ... Marriott Hotel on Tuesday, April 29th at 7:30 p.m. ... , The 2014 award winners are: ... Laitman, PhD, of the Icahn School of Medicine at ...
(Date:4/15/2014)... are many viral diseases in the world for which ... fever, which is spread by mosquitoes in the tropics, ... more familiar in Finland and is easily spread by ... children and the elderly. , Researchers at Aalto University ... in preliminary tests to prevent the spread of one ...
(Date:4/15/2014)... of cuttlefish, squid and octopus has uncovered details ... how they may help in investigating populations of ... described 10 new parasite species− dicyemid mesozoans −, ... squid and octopus). They are the very ... waters. , "Although dicyemid parasites have been ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2Bizarre parasite may provide cuttlefish clues 2
... 2012) Researchers from the University of Minnesota and Washington ... grain products in the United States may have an impact ... published online today in the journal Pediatrics , shows ... to increase, and also finds a notable decrease in two ...
... what makes one particular strain of methicillin-resistant Staphylococcus aureus ... as the one that makes it resistant to vancomycin, ... They report their findings in mBio , the ... on Tuesday May 22. "MRSA strains are leading ...
... Emerita, Stanford University School of Medicine, Stanford, California, has been ... for her years of volunteer service to ASM. "For as ... microbiology, Baron has been the heart and soul of my ... and Development, North America, for bioMrieux, Inc., Durham, NC. ...
Cached Biology News:Folic acid food enrichment potentially protective against childhood cancers 2How one strain of MRSA becomes resistant to last-line antibiotic 2The American Society for Microbiology honors Ellen Jo Baron 2The American Society for Microbiology honors Ellen Jo Baron 3
... Degranulation, the secretion of cytoplasmic granules, ... inflammatory response of leukocytes (e.g. basophils, ... addition to histamine, these secretory granules ... cytokines, chemokines, and many proteases (Hallgren, ...
... These are just some the things youll ... of Protein-Protein Interactions, edited by Erica Golemis, One ... skillfully edited compilation of topics in protein interaction ... text that must be a part of your ...
... In 1959, McCoy and his ... requirements for in vitro cultivation ... studies were performed using,Basal Medium ... create a new medium known ...
Schneider's Drosophila - Insect medium...
Biology Products: